Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
December 31, 2025 96.84%
September 30, 2025 98.52%
June 30, 2025 97.89%
March 31, 2025 96.93%
December 31, 2024 99.01%
September 30, 2024 97.17%
June 30, 2024 97.09%
March 31, 2024 77.71%
December 31, 2023 95.62%
September 30, 2023 95.66%
June 30, 2023 78.33%
March 31, 2023 82.06%
December 31, 2022 83.34%
September 30, 2022 84.64%
June 30, 2022 84.29%
March 31, 2022 82.64%
December 31, 2021 87.02%
September 30, 2021 86.97%
June 30, 2021 84.16%
March 31, 2021 83.83%
December 31, 2020 94.05%
September 30, 2020 95.08%
June 30, 2020 94.83%
March 31, 2020 88.96%
December 31, 2019 94.25%
Date Value
September 30, 2019 93.87%
June 30, 2019 94.22%
March 31, 2019 91.91%
December 31, 2018 93.32%
September 30, 2018 93.19%
June 30, 2018 92.37%
March 31, 2018 92.63%
December 31, 2017 93.13%
September 30, 2017 92.35%
June 30, 2017 92.53%
March 31, 2017 92.21%
December 31, 2016 92.68%
September 30, 2016 91.76%
June 30, 2016 94.35%
March 31, 2016 92.87%
December 31, 2015 95.10%
September 30, 2015 94.32%
June 30, 2015 95.05%
March 31, 2015 94.93%
December 31, 2014 95.32%
September 30, 2014 94.94%
June 30, 2014 98.09%
March 31, 2014 94.93%
December 31, 2013 92.95%
September 30, 2013 98.74%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Agenus, Inc. 98.50%
Amgen, Inc. 72.08%
BioCryst Pharmaceuticals, Inc. 98.01%
Imunon, Inc. --
CEL-SCI Corp. --

Gross Profit Margin (Quarterly) Related Metrics